X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the merger, TuHURA will focus on the clinical development of the IFx-Hu2.0 (IFx-2.0) vaccine in combination with Keytruda for the treatment of advanced Merkel cell carcinoma.
Lead Product(s): IFx-2.0,Pembrolizumab
Therapeutic Area: Oncology Product Name: IFx-Hu2.0
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: TuHURA Biosciences
Deal Size: $31.0 million Upfront Cash: Undisclosed
Deal Type: Merger April 03, 2024
Details:
The net proceeds from the funding will be used to upport the clinical development of REM-001, a second-generation photodynamic therapy photosensitizer agent for the treatment of cutaneous metastatic breast cancer (CMBC).
Lead Product(s): REM-001
Therapeutic Area: Oncology Product Name: REM-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 28, 2023
Details:
VAL-083 (dianhydrogalactitol) is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
Kintara intends to use any net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 (dianhydrogalactitol) and REM-001.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lincoln Park Capital Fund
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Agreement August 03, 2022
Details:
VAL-083 (Dianhydrogalactitol), first-in-class, small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
VAL-083 (dianhydrogalactitol) is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
The Company currently intends to use the net proceeds from the offering for funding its clinical studies, of two programs are VAL-083 for glioblastoma (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC) and other general corporate purposes.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $8.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 14, 2022
Details:
VAL-083 is a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors in U.S. clinical trials.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
VAL-083 is a "first-in-class", small-molecule, bifunctional alkylating agent that crosses the blood-brain-barrier and has a novel mechanism of action that has demonstrated clinical activity against a range of cancers.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
VAL-083 is independent of the MGMT resistance mechanism and has been assessed in over 40 Phase 1 and Phase 2 clinical trials in multiple indications sponsored by the U.S. National Cancer Institute (NCI).
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Yat-sen University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
